Johnson & Johnson Vision Launches Next-Gen Extended Depth of Focus IOLs with Mainland China’s First Implants in Boao

BOAO, Hainan, Aug. 1, 2021 /PRNewswire/ -- Johnson & Johnson Surgical Vision -- Johnson & Johnson Vision announced today that its new generation of enhanced extended depth of focus (EDOF) intraocular lens (IOL) family has officially launched at the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. As an advanced international medical technology specially approved for import, two first-ever implantation surgeries in mainland China were successfully completed at the International Optometry and Ophthalmology Center of Boao Super Hospital.

This series includes two groundbreaking innovative products from Johnson & Johnson Vision—the TECNIS Synergy, a next-generation extended depth of focus intraocular lens featuring an enhanced diffractive grating integrated with multifocal technology, and the TECNIS Eyhance, the first-generation extended depth of focus intraocular lens with a diffractive-ring-free design, which are used for intraocular lens implantation in ophthalmic surgery to help patients achieve clear vision across all distances.

Johnson & Johnson Vision's Next-Generation Enhanced Extended Depth of Focus (EDOF) Intraocular Lens Series Completes First Implantation at Boao Super Hospital (Draft)

"We are pleased to see that TECNIS "The successful inaugural implantation of the two new intraocular lenses, Eyhance and TECNIS Synergy, in Boao, Hainan, China, marks a significant step forward for the upcoming real-world data study," stated Dr. Xiaoyu Song, Global Head of R&D at Johnson & Johnson Vision. "Both intraocular lenses are built upon the solid foundation of the Johnson & Johnson Vision TECNIS IOL family, and will provide patients with enhanced contrast sensitivity, reduced optical interference, and address specific unmet visual needs. TECNIS Eyhance and TECNIS Since its global launch, Synergy has been widely recognized and highly praised by ophthalmology professionals. We look forward to these two innovative technologies becoming available to and benefiting the vast number of cataract patients in China at the earliest opportunity.”

Johnson & Johnson Vision Next-Generation Enhanced Extended Depth of Focus Intraocular Lens Series

Cataract is the leading cause of blindness worldwide, and surgery remains the only scientifically validated treatment for the condition. With continuous advancements in science and technology, cataract surgery has transitioned from the era of vision-restorative surgery to the era of refractive surgery. Consequently, an increasing number of patients expect not only to regain vision postoperatively, but to see clearly and achieve high-quality visual outcomes. This places increasingly stringent demands on surgical precision and intraocular lens (IOL) technology.

According to Professor Chen Wei, lead surgeon of the inaugural procedure, Vice President of the Eye Hospital of Wenzhou Medical University, and Director of the Ophthalmology Center at Boao Super Hospital: “Today’s surgery proceeded very smoothly, utilizing the globally advanced new-generation enhanced continuous range-of-vision intraocular lens series. Specifically, the Synergy lens incorporates the patented Echelette diffractive grating technology for EDOF continuous-vision IOLs along with multifocal IOL technology. It can provide high-quality, complete continuous visual acuity of 0.8 or better across a range from 33 cm to distance for patients undergoing cataract surgery or presbyopia correction. While simulating the natural eye, it enhances image contrast sensitivity and improves visual quality under low-light conditions. Meanwhile, the Eyhance lens adopts a diffractive-ring-free design. While delivering enhanced intermediate vision, it does not increase the incidence of optical interference, thereby meeting the daily visual requirements of most patients.”

Professor Chen Wei, Vice President of the Eye Hospital of Wenzhou Medical University and Director of the Ophthalmology Center at Boao Super Hospital, performs surgery on a patient.

“This marks another significant milestone in the accelerated advancement of the ‘Johnson & Johnson Boao Innovation Chain’ strategy, following the regulatory approval of Johnson & Johnson Vision’s ‘Catalys’ femtosecond laser ophthalmic treatment system through the Boao Real-World Data study,” said Wang Liping, Vice President of Johnson & Johnson Vision for Greater China, Australia and New Zealand. “As a global leader in the eye health industry, Johnson & Johnson Vision remains committed to bringing cutting-edge technologies and innovative products to China, improving people’s eye health, and upholding Johnson & Johnson’s Credo commitment.”

Johnson & Johnson is one of the earliest multinational healthcare companies to partner with the Boao Lecheng Pilot Zone, introducing internationally cutting-edge innovative products to the region. In December 2019, it officially launched the "Johnson & Johnson Boao Innovation Chain," dedicated to establishing an innovative comprehensive platform within the Boao Lecheng International Medical Tourism Pilot Zone that integrates the exhibition of medical research achievements, technology promotion, product application, academic exchange, and training of high-caliber specialized talents.

“In response, Gu Gang, Director of the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration, stated: “Lecheng possesses unique policy advantages, while Johnson & Johnson boasts robust R&D capabilities and a comprehensive product pipeline. The collaboration between both parties is expected to accelerate the introduction and commercialization of innovative achievements, including overseas medical devices and products. The Lecheng Pilot Zone will continue to welcome partnerships with leading global healthcare enterprises to build an open hub for medical and healthcare services, introduce more advanced pharmaceuticals and medical devices, and serve more patients.””

Innovation has been the enduring core competitive advantage driving Johnson & Johnson’s advancement of global health for over 130 years, and a key catalyst for its rapid growth in China over the past three decades. As a global leader in the healthcare industry, Johnson & Johnson is committed to introducing innovative technologies, solutions, and advanced manufacturing expertise to China. Guided by Our Credo, Johnson & Johnson Vision will continue to dedicate itself to the research and development of innovative medical technologies, accelerate the commercialization of innovative products in China, better address the unmet eye health needs of Chinese patients, and contribute to the Healthy China initiative.

##

About Johnson & Johnson

Founded in 1886, Johnson & Johnson is one of the most comprehensive and globally diversified healthcare companies in the world, with business operations spanning three major sectors: medical devices, pharmaceuticals, and consumer products. Headquartered in New Brunswick, New Jersey, USA, the company operates more than 260 affiliates across 60 countries and regions worldwide. It employs over 130,000 people globally, reported $82.6 billion in global revenue in 2020, and invested $12.2 billion in global research and development.

Johnson & Johnson firmly believes that health is the foundation of vibrant lives, thriving communities, and continuous progress. For this reason, for over 130 years, the company has remained dedicated to advancing health, enabling individuals to maintain their well-being at every age and stage of life. Today, as a comprehensive multinational healthcare enterprise with a broad global footprint, Johnson & Johnson is committed to leveraging its extensive influence to advance human health and build a better society. While striving to enhance the accessibility and affordability of medicines, foster healthier communities, and empower people worldwide to achieve physical and mental well-being within a healthy environment, the company embraces its mission to integrate compassion, science, and wisdom to drive transformative change in the advancement of human health.

In 1985, as one of the first multinational corporations to enter the Chinese market following the reform and opening-up policy, Johnson & Johnson established Xi'an Janssen Pharmaceutical Ltd. in China. Over the years, Johnson & Johnson has remained committed to delivering high-quality, innovative products to meet growing healthcare needs, improving the well-being of patients and consumers in China, and advancing the Healthy China initiative. Today, all of Johnson & Johnson's global business segments—including Medical Devices, Pharmaceuticals, Consumer Health, and Vision Care—have established a presence in China, with each operating as a market leader in its respective sector. Currently, Johnson & Johnson operates over 10 legal entities and nine major supply chain hubs across China, located in cities such as Beijing, Shanghai, Guangzhou, Suzhou, and Xi'an, with a workforce of approximately 11,000 employees.

Johnson & Johnson's Greater China headquarters is located in Shanghai, where the company operates multiple registered entities and manufacturing facilities across districts including Xuhui, Pudong New Area, and Minhang, ranking among the top 100 foreign-invested enterprises in Shanghai for tax contributions. As J&J's fastest-growing market globally, China was officially positioned as a global innovation engine in 2019 following an announcement by the J&J Global Executive Committee in Beijing. Additionally, J&J serves as a leading enterprise supporting the Shanghai municipal government’s initiative to build a global science and technology innovation center. Operating as one of J&J’s four global open innovation platforms, Shanghai leverages the company’s regional strengths alongside its Asia-Pacific and global resources and expertise to foster local startups and deliver breakthrough healthcare solutions to patients and consumers worldwide. In 2021, J&J China was officially recognized by the Shanghai municipal government as the first foreign-invested open innovation platform.

About Johnson & Johnson Vision

Leveraging Johnson & Johnson Advanced Medical Optics (AMO manufacturingUSA. LLC and other companies' Advanced Medical Optics (AMO) business was acquired by Johnson & Johnson in 2016) and the Vision Care business, currently, Johnson & Johnson Vision serves over 60 million patients daily across more than 100 countries and regions, dedicated to helping more people see more clearly, communicate more effectively, and live better lives.

Johnson & Johnson Vision's business portfolio encompasses surgical procedures for cataract and laser refractive surgery. Through continuous investment in innovative research and development, Johnson & Johnson Vision consistently launches breakthrough products and technologies, including the first known monofocal aspheric intraocular lens (IOL) capable of providing intermediate vision, next-generation extended depth of focus (EDOF) IOLs for cataract surgery combined with presbyopia correction, and the Catalys femtosecond laser ophthalmic treatment system.

Johnson & Johnson Vision is one of the pioneering innovators to introduce the world’s first replacement contact lenses. Through its globally renowned ACUVUE® brand portfolio, it helps more people see the world more clearly. In June 2019, driven by two groundbreaking innovations—the TECNIS Symfony® Extended Range of Vision Intraocular Lens and the ACUVUE® OASYS® with Transitions™ light-intelligent contact lenses under Johnson & Johnson Vision—Johnson & Johnson was honored with the title of 2019 Global "Smartest Company" by MIT Technology Review, becoming the sole company selected in the medical device category on the list.